A prospective evaluation of C-peptide levels and colorectal adenoma incidence

Murphy, Neil; Cross, Amanda J.; Huang, Wen‐Yi; Rajabzadeh-Heshejin, Vian; Stanczyk, Frank Z.; Hayes, Richard B.; Gunter, Marc J.

doi:10.1016/j.canep.2014.12.011

Cited by 5 publications

(1 citation statement)

References 30 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent meta-analysis of 4 cohorts and 10 case-control studies found no associations between adenoma and 3 most studied circulating inflammation markers CRP, IL-6, and TNF-α [136]. Similarly, no significant associations were found for C-peptide, GM-CSF, interferon-α (IFN-α), IL-1β, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-17A, MIP-1β, and vascular endothelial growth factor and adenoma [137][138][139]. Although associations were reported for IFN-α2, IL-7, IL-8, MCP-3, and SIL-4R in cross-sectional analyses [137,140] they have not been prospectively confirmed.…”

Section: Circulating Inflammation Markersmentioning

confidence: 98%

Colorectal Adenomas—Genetics and Searching for New Molecular Screening Biomarkers

Siskova

Červená

Král

et al. 2020

IJMS

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a malignant disease with an incidence of over 1.8 million new cases per year worldwide. CRC outcome is closely related to the respective stage of CRC and is more favorable at less advanced stages. Detection of early colorectal adenomas is the key to survival. In spite of implemented screening programs showing efficiency in the detection of early precancerous lesions and CRC in asymptomatic patients, a significant number of patients are still diagnosed in advanced stages. Research on CRC accomplished during the last decade has improved our understanding of the etiology and development of colorectal adenomas and revealed weaknesses in the general approach to their detection and elimination. Recent studies seek to find a reliable non-invasive biomarker detectable even in the blood. New candidate biomarkers could be selected on the basis of so-called liquid biopsy, such as long non-coding RNA, microRNA, circulating cell-free DNA, circulating tumor cells, and inflammatory factors released from the adenoma into circulation. In this work, we focused on both genetic and epigenetic changes associated with the development of colorectal adenomas into colorectal carcinoma and we also discuss new possible biomarkers that are detectable even in adenomas prior to cancer development.

show abstract